Drug intelligence / Profile preview

GS-5290

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

GS-5290 (formerly known as MBX-002) is an investigational, first-in-class monoclonal antibody agonist targeting the B- and T-lymphocyte attenuator (BTLA) receptor. Developed by Gilead Sciences following its acquisition of MiroBio in 2022, the drug is designed to restore immune homeostasis by selectively activating the BTLA inhibitory pathway. BTLA is an immune checkpoint receptor expressed on T and B cells that, when activated, provides inhibitory signals to dampen overactive immune responses. GS-5290 aims to mimic the natural inhibitory signaling of the BTLA pathway to treat autoimmune and inflammatory diseases. It is currently being evaluated in early-phase clinical trials for the treatment of ulcerative colitis, with the goal of inducing mucosal healing and clinical remission by suppressing pathological lymphocyte activation in the gut.

Other names: BTLA agonist antibody

Targets

MAP3K8

Beyond the preview

Go deeper on GS-5290.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-5290.

Explore the full profile